Opportunity Information: Apply for RFA DA 13 002
Apply for RFA DA 13 002
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Apr 24, 2012 and posted on Apr 24, 2012.
- Applicants must submit their applications by Jan 17, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Independent school districts Public and State controlled institutions of higher education Small businesses Private institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) is a National Institutes of Health (NIH) funding opportunity from the National Institute on Drug Abuse (NIDA) designed to back individual investigators who are unusually creative and capable of pushing the HIV/AIDS field in new directions, specifically in ways that matter for people who use drugs. The program is built around the idea of "avant garde" science: proposals are expected to be highly innovative, potentially transformative, and meaningfully different from what the applicant or other researchers are already doing. Rather than incremental advances, NIDA is looking for big, high-impact ideas that could open entirely new areas of HIV/AIDS research or create new paths toward prevention and treatment of HIV/AIDS in drug-using populations.
A central requirement is that the research topic align with priorities described in the Trans-NIH Plan for HIV-Related Research (referenced in the announcement through the Office of AIDS Research strategic plan link). In practical terms, this means applicants should be able to clearly connect their proposed work to broader NIH HIV/AIDS research priorities, while still making the case that their approach is unusually original. The emphasis on drug abuse is not incidental; the opportunity is explicitly aimed at advancing HIV/AIDS prevention and treatment approaches that are relevant to drug abusers and the real-world contexts that increase HIV risk or complicate care in those communities.
Administratively, this opportunity is listed as Funding Opportunity Number RFA-DA-13-002, with the title "FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1)." It is a discretionary grant program under the NIH umbrella, categorized in the health and education funding activity areas, and linked to CFDA 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement, which means applicants are not required to contribute non-federal funds as a condition of the award.
The funding details indicate an estimated total funding amount of $2,000,000 for the competition, with an award ceiling of $500,000. This suggests NIDA anticipated making a small number of sizable awards, consistent with the program's focus on backing exceptional investigators and high-risk, high-reward concepts rather than funding many smaller, conventional projects. The opportunity was posted on April 24, 2012, and the application closing date was January 17, 2013, with an archive date of February 17, 2013, meaning it was a time-limited solicitation for that fiscal year.
Eligibility is broad and includes a wide range of domestic U.S. organizations such as public and private institutions of higher education, nonprofits with or without 501(c)(3) status (including those outside higher education), for-profit organizations other than small businesses, small businesses, and multiple levels of government (state, county, city or township, special districts, and independent school districts). It also includes public housing authorities/Indian housing authorities and tribal entities, including federally recognized tribal governments and tribal organizations, as well as tribally controlled colleges and universities. The announcement further clarifies additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Notably, the program also allows participation by non-U.S. entities: foreign institutions may apply, non-domestic components of U.S. organizations are eligible, and foreign components are allowed as defined by the NIH Grants Policy Statement. This international openness aligns with the global scope of HIV/AIDS while keeping the research focus tied to NIDA's mission and drug-use-related HIV challenges.
For applicants or readers who need the full official announcement and application instructions, the solicitation provides an additional information link to the NIH grants page hosting the RFA text (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-13-002.html). For technical issues accessing the announcement or problems with links, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) (RFA-DA-13-002)
What is this funding opportunity?
The FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) is a National Institutes of Health (NIH) funding opportunity from the National Institute on Drug Abuse (NIDA). It is intended to support individual investigators whose work is unusually creative and capable of pushing HIV/AIDS research in new directions, specifically in ways that matter for people who use drugs.
What is the official funding opportunity number and title?
The Funding Opportunity Number is RFA-DA-13-002. The title is "FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1)."
Which agency is offering this award?
This opportunity is offered under the NIH umbrella by NIDA (National Institute on Drug Abuse).
What kind of research is NIDA looking for under this program?
NIDA is looking for highly innovative, potentially transformative HIV/AIDS research that is meaningfully different from what the applicant or other researchers are already doing. The emphasis is on big, high-impact ideas rather than incremental advances, with relevance to prevention and treatment of HIV/AIDS in drug-using populations and the real-world contexts that increase HIV risk or complicate care.
What does "avant garde" mean in the context of this program?
In this program, "avant garde" refers to proposals that are expected to be highly innovative and potentially transformative. The work should push the field in new directions and open new areas of HIV/AIDS research or create new paths toward prevention and treatment for populations affected by drug use.
Does the research have to address drug use or drug-using populations?
Yes. The opportunity is explicitly aimed at advancing HIV/AIDS prevention and treatment approaches that are relevant to drug abusers and the real-world contexts that increase HIV risk or complicate care in those communities.
Are there specific NIH priorities the project must align with?
Yes. A central requirement is that the research topic align with priorities described in the Trans-NIH Plan for HIV-Related Research (referenced in the announcement through the Office of AIDS Research strategic plan link). Applicants are expected to clearly connect their proposed work to broader NIH HIV/AIDS research priorities while also demonstrating an unusually original approach.
What is the CFDA number associated with this opportunity?
The opportunity is linked to CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
How much funding is available in total, and what is the maximum award size?
The estimated total funding amount for the competition is $2,000,000, and the award ceiling is $500,000.
What does the stated total funding and award ceiling suggest about the number of awards?
With an estimated total of $2,000,000 and an award ceiling of $500,000, NIDA anticipated making a small number of sizable awards. This aligns with the program's goal of backing exceptional investigators and high-risk, high-reward ideas rather than funding many smaller, conventional projects.
When was the opportunity posted, and what were the key dates?
The opportunity was posted on April 24, 2012. The application closing date was January 17, 2013. The archive date was February 17, 2013.
Is this opportunity still open?
Based on the provided dates, it was a time-limited solicitation for that fiscal year and was archived on February 17, 2013.
What types of U.S. organizations are eligible to apply?
Eligibility includes a wide range of domestic U.S. organizations, including public and private institutions of higher education; nonprofits with or without 501(c)(3) status (including those outside higher education); for-profit organizations other than small businesses; small businesses; and multiple levels of government (state, county, city or township, special districts, and independent school districts). Public housing authorities/Indian housing authorities are also eligible.
Are tribal governments and tribal organizations eligible?
Yes. The opportunity includes tribal entities such as federally recognized tribal governments and tribal organizations, as well as tribally controlled colleges and universities.
Are minority-serving institutions and community-based organizations eligible?
Yes. The announcement clarifies eligibility for Alaska Native and Native Hawaiian Serving Institutions, Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, and faith-based or community-based organizations. Regional organizations are also included.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are listed among eligible applicants.
Are federal agencies eligible to apply?
Yes. The eligibility list includes eligible federal agencies.
Can foreign (non-U.S.) institutions apply?
Yes. The program allows participation by non-U.S. entities: foreign institutions may apply, non-domestic components of U.S. organizations are eligible, and foreign components are allowed as defined by the NIH Grants Policy Statement.
Where can applicants find the official announcement and instructions?
The solicitation provides an NIH grants page hosting the full RFA text: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-13-002.html
Who should be contacted for technical problems accessing the announcement or link issues?
For technical issues accessing the announcement or problems with links, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
How is this opportunity categorized in terms of funding activity areas?
It is categorized in the health and education funding activity areas.
What is the main goal of this program in plain terms?
The main goal is to accelerate unusually original HIV/AIDS research that could change the field, with a specific focus on prevention and treatment approaches that are relevant to people who use drugs and the settings and conditions that shape HIV risk and care in those communities.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Maine Conservation Innovation Grant FY12
Previous opportunity: Pre Application for the FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (X02)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 13 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 13 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Identifying Health Outcomes Associated with Changes in Use of Illicit Drugs (R01) Apply for RFA DA 13 007 Funding Number: RFA DA 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Synthesis and Preclinical Evaluation of Medications to Treat Substance Use Disorders (SUDs) (R01) Apply for RFA DA 13 004 Funding Number: RFA DA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44) Apply for PA 12 196 Funding Number: PA 12 196 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Clinical Oncology Program Groups (U10) Apply for RFA CA 12 007 Funding Number: RFA CA 12 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program Groups (U10) Apply for RFA CA 12 008 Funding Number: RFA CA 12 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIMH Career Transition Award for Tenure Track and Tenured Intramural Investigators (K22) Apply for PAR 12 201 Funding Number: PAR 12 201 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25) Apply for PAR 12 199 Funding Number: PAR 12 199 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co morbidities (R21) Apply for RFA AI 12 033 Funding Number: RFA AI 12 033 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Establish Sharing of Human Brain Image Data Relevant to Drug Addiction (Admin Supp) Apply for PAR 12 204 Funding Number: PAR 12 204 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 13 008 Funding Number: RFA DA 13 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R01) Apply for PA 12 213 Funding Number: PA 12 213 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R21) Apply for PA 12 214 Funding Number: PA 12 214 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 12 220 Funding Number: PA 12 220 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 12 221 Funding Number: PA 12 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 13 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.